Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
1 "Yilmaz Faki"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Article
Serum Visfatin and Fetuin-A Levels and Glycemic Control in Patients with Obese Type 2 Diabetes Mellitus
Fethiye Oztop Gunduz, Sembol Turkmen Yildirmak, Mustafa Temizel, Yilmaz Faki, Mustafa Cakmak, Mustafa Durmuscan, Funda Sezgin
Diabetes Metab J. 2011;35(5):523-528.   Published online October 31, 2011
DOI: https://doi.org/10.4093/dmj.2011.35.5.523
  • 65,535 View
  • 29 Download
  • 10 Crossref
AbstractAbstract PDFPubReader   
Background

Visfatin is an adipokine produced by visceral adipose tissue and has insulin-mimicking effects. Fetuin-A is a hepatic secretory protein that binds the insulin receptor and inhibits insulin action both in vivo and in vitro. The authors of the present study aimed to investigate the levels of serum visfatin and fetuin-A and their correlation with hemoglobin A1c (HbA1c) and urine albumin levels in patients with type 2 diabetes mellitus (T2DM).

Methods

A total of 40 obese patients with T2DM (11 males and 29 females; age, 54.47±10.83 years and 23 obese nondiabetic controls (8 males and 15 females; age, 53.04±11.33 years) were included in the study. Age, sex, and body mass index were similar in the 2 groups. Serum visfatin and fetuin-A levels were measured by enzyme-linked immunosorbent assay. HbA1c and urine albumin levels were measured by high performance liquid chromatography and nephelometric method, respectively.

Results

Serum levels of visfatin in patients with T2DM (4.03±2.44 ng/mL) were similar to the control group (3.65±3.02 ng/mL). Serum fetuin-A levels were significantly lower in patients with T2DM than the controls (298.75±78.86 and 430.73±94.46 µg/mL, respectively). HbA1c levels were significantly higher in the T2DM group compared with controls (7.33±1.32 and 5.44±0.84%, respectively). Correlations between visfatin, fetuin-A and HbA1c levels were not observed.

Conclusion

The present study suggests fetuin-A may play a role in the pathogenesis of T2DM.

Citations

Citations to this article as recorded by  
  • Assessment of serum and salivary visfatin levels in newly diagnosed patients of type-II DM
    Faith R. Jerusha, Vandana Raghunath
    Journal of Oral and Maxillofacial Pathology.2023; 27(4): 663.     CrossRef
  • Evaluation of the serum visfatin eotaxin and fetuin-A levels of patients with type 2 diabetes mellitus
    Hacer KAYHAN KAYA, Abdurrahman ŞERMET, Zafer PEKKOLAY, Ezel TAŞDEMİR, Dilek AYGÜN KEŞİM
    Anatolian Current Medical Journal.2022; 4(1): 113.     CrossRef
  • The Association Between Three Adipocytokines (Adiponectin, Resistin and Visfatin) And Thyroid Status in Patients With Type 2 Diabetes Mellitus and Autoimmune Thyroiditis
    Š. Sotak, Z. Schroner, I. Lazúrová, M. Felšőci, I. Jochmanová, D. Petrášová, I. Bertková, M. Mitníková, B. Nováková, H. Wagnerová, O. Bobelová
    Physiological Research.2021; (6): 865.     CrossRef
  • Prediction of gestational diabetes mellitus in the first trimester: comparison of maternal fetuin-A, N-terminal proatrial natriuretic peptide, high-sensitivity C-reactive protein, and fasting glucose levels
    Hatice Kansu-Celik, A. Seval Ozgu-Erdinc, Burcu Kisa, Rahime Bedir Findik, Canan Yilmaz, Yasemin Tasci
    Archives of Endocrinology and Metabolism.2019;[Epub]     CrossRef
  • The association between circulating fetuin-A levels and type 2 diabetes mellitus risk: systematic review and meta-analysis of observational studies
    F. Roshanzamir, M. Miraghajani, M. H. Rouhani, M. Mansourian, R. Ghiasvand, S. M. Safavi
    Journal of Endocrinological Investigation.2018; 41(1): 33.     CrossRef
  • Fetuin-A level in type 2 diabetic patients: relation to microvascular complications
    Nehal H. Al-Said, Fatma M. Taha, Ghada M. Abdel-Aziz, Marwa S. Abdel-Tawab
    The Egyptian Journal of Internal Medicine.2018; 30(3): 121.     CrossRef
  • Serum levels of fetuin A are increased in women with gestational diabetes mellitus
    Ozlem Turhan Iyidir, Ceyla Konca Degertekin, Banu Aktas Yilmaz, Alev E. Altinova, Fusun B. Toruner, Nuray Bozkurt, Goksun Ayvaz, Mujde Akturk
    Archives of Gynecology and Obstetrics.2015; 291(4): 933.     CrossRef
  • Lower Fetuin-A, Retinol Binding Protein 4 and Several Metabolites after Gastric Bypass Compared to Sleeve Gastrectomy in Patients with Type 2 Diabetes
    Mia Jüllig, Shelley Yip, Aimin Xu, Greg Smith, Martin Middleditch, Michael Booth, Richard Babor, Grant Beban, Rinki Murphy, Pankaj K. Singh
    PLoS ONE.2014; 9(5): e96489.     CrossRef
  • Preventive roles of swimming exercise and pioglitazone treatment on hepatic dysfunction in a rat model of metabolic syndrome
    Hussein F. Sakr, Fahaid H. Al-Hashem, Waffaa M. Hassab El-Naby, Mahmoud A. Alkhateeb, Mohamed Samir A. Zaki, Hesham M. El Refaey, Mohamed D. Morsy
    Canadian Journal of Physiology and Pharmacology.2014; 92(2): 162.     CrossRef
  • Relationship between circulating visfatin/NAMPT, nutritional status and insulin resistance in an elderly population – results from the PolSenior substudy
    Magdalena Olszanecka-Glinianowicz, Aleksander Owczarek, Maria Bożentowicz-Wikarek, Aniceta Brzozowska, Małgorzata Mossakowska, Tomasz Zdrojewski, Tomasz Grodzicki, Andrzej Więcek, Jerzy Chudek
    Metabolism.2014; 63(11): 1409.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal